scholarly journals Growth-Differentiation Factor 15 Predicts Worsening of Albuminuria in Patients With Type 2 Diabetes

Diabetes Care ◽  
2012 ◽  
Vol 35 (11) ◽  
pp. 2340-2346 ◽  
Author(s):  
M. E. Hellemons ◽  
M. Mazagova ◽  
R. T. Gansevoort ◽  
R. H. Henning ◽  
D. de Zeeuw ◽  
...  
2020 ◽  
Author(s):  
Xingxing He ◽  
Jiaorong Su ◽  
Xiaojing Ma ◽  
Jingyi Lu ◽  
Yufei Wang ◽  
...  

Abstract Background: Recent studies noted that circulating growth differentiation factor 15 (GDF15) were closely related to metabolic states. The study aimed to explore the changes of GDF15 levels and their influencing factors after 4 weeks of lifestyle intervention (LI) or LI combined with breakfast meal replacement (LI+MR) in newly diagnosed type 2 diabetes patients. Methods: A total of 84 patients with available serum samples at both baseline and Week 4 were enrolled in this biomarker substudy. All subjects underwent a 2-hour 75g oral glucose tolerance test at baseline and Week 4. Serum GDF15 levels were determined by a sandwich enzyme-linked immunosorbent assay. Results: After 4-weeks of LI, GDF15 levels overall significantly decreased compared with baseline (P<0.05). ∆GDF15 levels were significantly and negatively associated with baseline GDF15 levels (r=–0.450, P<0.001). The optimal cut-off point of baseline GDF15 levels for predicting a GDF15 decrease after 4-weeks of LI was 904.57 pg/ml, with an area under curve of 0.699. Based on the cut-off point of 900 pg/ml, patients with baseline GDF15 ≥900 pg/ml had significantly decreased GDF15 levels after LI, while those <900 pg/ml had no significant changes. Regression models showed that baseline GDF15 level was an independent positive factor for the improvement of fasting plasma glucose and homeostasis model assessment for insulin resistance only in patients with baseline GDF15 levels ≥900 pg/ml. Conclusions: LI led to significantly decreased GDF15 levels among patients with newly diagnosed type 2 diabetes and its effect was more significant among patients with baseline GDF15 levels ≥900 pg/ml.Trial registration: ClinicalTrials.gov, NCT02248714. Registered 25 September 2014 - Retrospectively registered, https://www.clinicaltrials.gov/ct2/show/NCT02248714?term=NCT02248714&draw=2&rank=1


2016 ◽  
Vol 40 (1) ◽  
pp. 70 ◽  
Author(s):  
Ji Min Kim ◽  
Min Kyung Back ◽  
Hyon-Seung Yi ◽  
Kyong Hye Joung ◽  
Hyun Jin Kim ◽  
...  

Oncotarget ◽  
2017 ◽  
Vol 8 (25) ◽  
pp. 41379-41386 ◽  
Author(s):  
Hongmei Zhang ◽  
Weiwei Zhang ◽  
Xiaofang Tu ◽  
Yixin Niu ◽  
Xiaoyong Li ◽  
...  

PLoS ONE ◽  
2018 ◽  
Vol 13 (4) ◽  
pp. e0196634 ◽  
Author(s):  
Marie Frimodt-Møller ◽  
Bernt Johan von Scholten ◽  
Henrik Reinhard ◽  
Peter Karl Jacobsen ◽  
Tine Willum Hansen ◽  
...  

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Jin Ook Chung ◽  
Seon-Young Park ◽  
Dong Hyeok Cho ◽  
Dong Jin Chung ◽  
Min Young Chung

AbstractThe purpose of our study was to investigate the relationship between plasma growth differentiation factor-15 (GDF-15) concentrations and diabetic retinopathy in patients with type 2 diabetes mellitus (DM). We evaluated 235 patients with type 2 DM in a cross-sectional study. Significantly increased levels of the plasma GDF-15 were found in individuals with diabetic retinopathy versus those without. According to the degree of diabetic retinopathy, there was a significant difference in the average plasma GDF-15 levels (no diabetic retinopathy, 1114 ng/L; nonproliferative diabetic retinopathy, 1327 ng/L; proliferative diabetic retinopathy, 1445 ng/L; p for trend = 0.035) after adjustments for confounders. Logistic regression analyses indicated that plasma GDF-15 concentrations were significantly associated with diabetic retinopathy (odds ratio per 1 standard deviation increment in the log-transformed value, 1.78; 95% confidence interval, 1.05–3.03, p = 0.032). Our study showed a significant positive relationship between plasma GDF-15 concentrations and diabetic retinopathy in type 2 DM patients.


Sign in / Sign up

Export Citation Format

Share Document